Back to top

Image: Bigstock

Plug Power (PLUG) to Report Q4 Earnings: What to Expect?

Read MoreHide Full Article

Plug Power Inc. PLUG is scheduled to release fourth-quarter 2019 results on Mar 5, before market open.

The company delivered weaker-than-expected results in three of the last four quarters, while surpassing estimates in one. Earnings surprise for the last four quarters is a negative 40.21%, on average. Notably, in the last reported quarter, the company’s loss per share of 8 cents lagged the Zacks Consensus Estimate of 6 cents loss per share.

In the past three months, shares of the company have gained 32.1% against the industry’s decline of 6.2%.

Let us delve deeper.

Key Factors and Estimates

The growing popularity of fuel cell engines and hydrogen stations has been benefiting Plug Power over time. This is expected to have contributed to top-line performance in the fourth quarter of 2019. The company’s major product offerings include GenDrive fuel cell systems and ProGen fuel cell engine.

Also, healthy demand from material handling, on-road and stationary markets as well as technological advancements, and efforts to build additional capacity and strengthen sales channels might have been beneficial.

Further, the company’s partnership with ENGIE (signed in the third quarter) might have positively impacted the hydrogen fuel cell business in the quarter.

However, headwinds (like forex issues, geopolitical concerns and others) arising from international operations might have hurt the company’s quarterly performance. Also, higher cost revenues and operating expenses might have been dragging. Notably, cost of revenues and operating expenses increased 5.7% and 5.5%, respectively, in the first nine months of 2019.

Plug Power anticipates record gross billings of $93-$95 million for the fourth quarter. Notably, gross billings were just $61 million in the third quarter of 2019. Also, GenDrives deployment will likely be 2,500 in the quarter.

The Zacks Consensus Estimate for fourth-quarter loss per share is pegged at 6 cents, indicating an improvement from a loss per share of 8 cents recorded in the fourth quarter of 2018. However, the consensus estimate for revenues of $90 million suggests a 50% increase from the prior-year reported figure.

Earnings Whispers

Our proven model doesn’t conclusively predict an earnings beat for Plug Power this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of beating estimates. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Earnings ESP: Plug Power has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at loss per share of 6 cents.

Plug Power, Inc. Price and Consensus


Plug Power, Inc. Price and Consensus

Plug Power, Inc. price-consensus-chart | Plug Power, Inc. Quote

Zacks Rank: Plug Power currently carries a Zacks Rank #3.

Stocks to Consider

Here are some stocks worth considering as our model shows that these have the right combination of elements to beat on earnings.

Syndax Pharmaceuticals, Inc. (SNDX - Free Report) has an Earnings ESP of +2.70%.  Currently, it is a Zacks #2 Ranked stock. You can see the complete list of today’s Zacks #1 Rank stocks here.

NGM Biopharmaceuticals, Inc. NGM presently has an Earnings ESP of +32.35% and a Zacks Rank of 3.

Frontier Communications Corporation FTR currently has an Earnings ESP of +41.50% and a Zacks Rank #3.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Syndax Pharmaceuticals, Inc. (SNDX) - Free Report >>